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PDynamic fluid shifts induced by fetal bypass
R. Scott Baker, BS,a,b Christopher T. Lam, BS,a Emily A. Heeb,a and Pirooz Eghtesady, MD, PhDa,b,c
Objective: Fluid shifts have been suggested to occur with fetal bypass. The degree or mechanisms behind these
volume changes (or location) have not been defined.We characterized the preceding and correlated the findings to
plasma vasopressin concentrations, the critical peptide of osmoregulation.
Methods: Seventeen ovine fetuses (105–111 days’ gestation) were started on bypass and followed 2 hours after
bypass. Hemodynamics and volume replacements needed to maintain minimum reservoir volume during bypass
and normal physiologic parameters after bypass were recorded. Serial blood samples were collected to assess gas
exchange and vasopressin levels. Changes in total tissue water content were measured for several organs and the
placenta. Plasma volume, fluid shifts, and osmolarity were calculated.
Results: Hematocrit values decreased by 15 minutes of bypass to 28% from 33% and then increased to 34% by
120 minutes after bypass, corresponding to a decreased fetal plasma volume of 79 to 72 mL/kg by 120 minutes
after bypass. The majority of volume shifts (approximately 100 mL/kg) occurred during bypass, but additional
volume replacements were required after bypass to maintain normal hemodynamics, resulting in overall losses
of 0.8 mL $ kg1 $ min1. Losses were not accounted for by placental or organ edema. Vasopressin levels
increased dramatically with bypass (39–51.5 pg/mL) and were strongly predicted by increased fetal plasma vol-
umes (R2 ¼ 0.90), whereas osmolarity was not significantly associated with plasma volumes.
Conclusion: Fetal bypass leads to significant fluid shifts that correlate strongly with increasing vasopressin levels
(but not changes in osmolarity). The placenta is not the primary site of volume loss. Rehydration of the fetus is
necessary after bypass.
CARDIOPULMONARY SUPPORTEach year, several hundred thousand babies around theworld
are born with heart defects. Most of these defects are effec-
tively corrected through surgical intervention after birth;
however, some continue to be associated with significant
morbidity and mortality. There is increasing evidence that
some of these defects might benefit from fetal interventions,
including perhaps fetal cardiac surgery.1-3 Previous studies
have demonstrated the feasibility of fetal cardiac bypass.
Experimental studies of fetal cardiac surgery consistently
observe placental dysfunction after bypass.4-9 The mecha-
nism or mechanisms for this placental dysfunction remain
unknown,7,10,11 although inflammation, an inappropriate fe-
tal stress response, and activation of various biochemical
pathways, among others, have all been implicated.9,10,12-14
Some have also argued that fetal bypass leads to secondary
changes in the placenta, such as increased edema through
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erbate placental function further. The latter seems reasonable
in view of several reports of increased volume requirement
for the fetus supported by extracorporeal circulation.14-16
Such fluid losses are not surprising considering their re-
ported occurrence in other settings, such as neonatal cardiac
surgery,17-19 in which the inflammatory insults of bypass are
observed.
The magnitude and severity of such fluid losses with fetal
bypass, however, have not been characterized, nor is there
any information to quantify where these losses occur (and
whether the placenta is the primary site of fluid loss). The
mechanisms leading to fluid losses are not clear either. We
have previously shown that profound changes in vasopressin
release take place with the onset and progression of fetal
bypass.14 Vasopressin is a critical component of osmoregu-
lation and therefore potentially capable of inducing signifi-
cant fluid shifts. Uniquely, vasopressin receptors (but not
vasopressin itself) are expressed at high levels within the
placenta.20
With the preceding in mind, we set out to characterize the
magnitude of changes (and their potential location) in fetal
plasma volume and third-space fluid losses that occur with
fetal bypass. Furthermore, we looked at any potential corre-
lations of the preceding with changes in fetal plasma
vasopressin levels. We hypothesized that postbypass rehy-
dration of the fetus would be necessary for adequate fluid
regulation, especially in the setting of associated placental
dysfunction. Defining the role and contribution of each of
these components has significant implications for clinical
translation of fetal cardiac surgery.gery c March 2009
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PAbbreviations and Acronyms
PVR ¼ placental vascular resistance
TTW ¼ total tissue water
MATERIALS AND METHODS
Surgical Procedure
Twenty-six singleton and twin pregnant ewes from 104 to 114 days of
gestation (average weight, 1.5 kg) were studied (term, approximately 148
days). Seventeen fetuses underwent 30 minutes of extracorporeal circula-
tory support and were followed for 2 hours after bypass. Of these, 7 fetuses
were followed without any intervention, whereas 10 fetuses received treat-
ment, as defined by volume resuscitation in the postbypass period as needed
to maintain stable fetal hemodynamics. These bypass groups were com-
pared with 9 equally instrumented control animals that did not undergo ex-
tracorporeal circulatory support. Surgical preparation and fetal bypass were
performed as previously described by our group.5,9,14,21
Briefly, ewes are fasted for 24 hours before sedation with ketamine and
diazepam, endotracheal intubation, and anesthesia maintenance with 2% iso-
flurane and oxygen. Ewes receive 0.3mg of buprenorphine (Buprenex) admin-
istered intramuscularly and penicillin G. Catheters are placed in the maternal
femoral artery and vein for measurement of blood gases and delivery of intra-
venous fluids, respectively. After midline laparotomy and minor hysterotomy,
additional catheters are placed in the fetal femoral artery and vein for blood gas
measurements, blood sampling, and pressure monitoring and for fluid resusci-
tation. Through the same hysterotomy, an umbilical flowprobe (4–6mm;Tran-
sonic Systems, Ithaca, NY) is placed tomeasure placental blood flow. Placental
vascular resistance (PVR) is calculated as previously described.22
Fetal Bypass
Using methods we have previously described,5,9,14,21 fetal cannulation
was performed with a 10F to 12F Bio-Medicus (Eden Prairie, Minn) venous
cannula in the jugular vein and a 6F to 8F Bio-Medicus arterial cannula in the
carotid artery. Direct central cannulation is not used to avoid the risk of hem-
orrhage that can occur with central cannulation and that would secondarily
complicate the experimental model and observations because of required
transfusions. Hemodynamic values are continuously recorded with a Power-
Lab data acquisition system (ADInstruments, Colorado Springs, Colo).
Bypass is conducted with a roller pump system, with normothermia,
vacuum-assisted venous drainage, and a heat exchanger andwith the placenta
functioning as the sole oxygenator.We use blood prime for our circuit, which
is derived from a donor adult ewe (not maternal).5,9,14,21 Bypass is conducted
for 30 minutes, with a target flow rate of 200 to 250 mL $ kg1 $min1 based
on our prior studies (beating heart and continues to eject),5,9,14,21 and fetuses
are followed for 2 hours after bypass. The venous reservoir (Capiox Baby-
RX; Terumo, Ann Arbor, Mich) is filled with 125 mL of prime at baseline.
Thereafter, Plasmalyte-A (Baxter Healthcare Corp, Deerfield, Ill) solution
is added to the circuit to maintain a minimum level of 50 mL in the reservoir.
The remainder of the circuit consists of 1/4-inch tubingon the venous side and
3/16-inch tubing on the arterial side, and the pump head is brought as close as
possible to the field, analogous to a remote pump-head situation. Ewes and
fetuses are killed after the termination of the experimental protocol for au-
topsy assessment of fetal morphometrics and confirmation of catheter posi-
tions. All procedures in our laboratory are performed in accordance with
Institutional Animal Care and Use Committee–approved protocols, and our
laboratory is an Association for Assessment andAccreditation of Laboratory
Animal Care–approved facility.
Sampling Regimen
For the purposes of this study, fetal arterial blood was collected before
and after neck cannulation, at 15 and 30 minutes of bypass, and at 30, 60,The Journal of Thoracic and C90, and 120 minutes after bypass for determination of blood gases and he-
matocrit values with an i-STAT clinical analyzer (i-STAT Corp, Windsor,
NJ) and for glucose and lactate values with a YSI 2300-STAT analyzer
(YSI Corp, Yellow Springs, Ohio). Placental cotyledons from bypass ani-
mals were collected before bypass and 30 and 120 minutes after bypass,
wrapped in foil, and snap-frozen into liquid nitrogen for subsequent total tis-
sue water (TTW) weight analysis. Similarly, after death, fetal left and right
ventricles, lungs, livers, and kidneys were rapidly collected from bypass and
sham bypass control animals and frozen in liquid nitrogen for later TTW
analysis.
Vasopressin Measurement
Using methods we published previously,14 fetal blood samples for vaso-
pressin immunoassay were collected into lithium heparin–coated tubes
(4 mL each; Monovettes; Sarstedt, Newton, NC). These were immediately
placed on ice and centrifuged, and the separated plasma was frozen at20C
until assay. The commercially available vasopressin EIA assay kit (Assay
Designs, Ann Arbor, Mich) had a sensitivity of 3.5 pg/mL, with intra-assay
and interassay coefficients of variation of 5.9% to 10.6% and 6.0% to
8.5%, respectively. This assay is capable of recognizing sheep proteins,
and all results were read with a Multiskan-EX microplate reader (Thermo
EC, Waltham, Mass) and Ascent software (Thermo EC). All samples
were assayed in duplicate, and mean values are reported.
Calculations of Fluid Shift and Osmolarity
Fetal blood volume (FBV) was estimated as 11% of measured fetal body
weight.23 Prior studies of fluid extravasation with bypass in neonatal piglets
estimated blood volume by injecting a known volume of carbon monoxide
into the closed-circuit rebreathing system,17,24,25 but this method is not pos-
sible in the fetal setting. Fetal plasma volume (FPV) and fluid shifts (FS)
were calculated according to equations 1 and 2below by using measured
hematocrit (HCT) values:
FPV ¼ FBV 3 ð1½HCT=100Þ (1)
FS ¼ ðReservoir volume lost during by pass
þReplacement volumeþFOPVinitialÞFPVfinal
(2)
Osmolarity (cOsm) was calculated from measured sodium (Naþ) and
glucose values, as shown in equation 3.
cOsm ¼ 2 3 Naþþð½Glucose=18Þ (3)
Calculation of TTW
Placental cotyledons (n ¼ 4, bypass; n ¼ 4, control) and fetal lungs,
livers, kidneys, and left and right ventricles (n ¼ 6, bypass; n ¼ 4, control)
were examined. By using a variation of prior methods,17 each 0.5- to 1.5-g
sample of tissue was cut in 3 parallel pieces, placed on preweighed foil, and
put in a 70C drying chamber. Samples were weighed repeatedly until a sta-
ble weight was reached, usually within 48 hours. TTW is presented as both
gram/gram of dry weight and percentage of water weight. TTWs from heart,
lung, kidney, and liver tissue from noninstrumented control twins were
compared with those from animals exposed to bypass at 120 minutes after
bypass (ie, single time point). In contrast, serial comparisons could be car-
ried out for placental tissue (before and 30 and 120 minutes after), compar-
ing control animals and animals exposed to bypass.
Statistical Analysis
Longitudinal data were analyzed by means of mixed-models repeated-
measures analysis of variance with SAS Proc Genmod (SAS Institute,
Inc, Cary, NC), testing for between-group and within-group differencesardiovascular Surgery c Volume 137, Number 3 715
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Pover the course of the experiment. Least significant difference and Stu-
dent’s paired and 2-group t post-hoc tests were used to examine mean dif-
ferences between groups and changes between time points. R2 values,
measuring the amount of variation explained by a given model, were deter-
mined by using least-squares regression. We defined an R2 value of 0.7 or
greater to be indicative of a strong predictor. Values are presented as the
mean  standard deviation. Software packages SAS 9.13, SPSS 15.0
(SPSS, Inc, Chicago, Ill), and Excel 2003 (Microsoft, Redmond, Wash)
were used for data analysis. P values for post-hoc analyses must be viewed
critically by the reader because the analyses were not preplanned and have
not been adjusted for multiple comparisons. The analyses were performed
to help describe the differences in mean values seen over time and between
groups. Any significance of these results must be interpreted within this
framework.
RESULTS
Fetal Hemodynamics and Placental Gas Exchange
Fetal hemodynamics with the conduct of bypass are
shown in Table 1. Fetal mean arterial pressure increased
acutely and profoundly during bypass, returning to baseline
levels after bypass and then decreasing further by 120 min-
utes after bypass. Individual umbilical blood flow responses
to the onset of fetal bypass were variable but, with termina-
tion of bypass, always returned to prebypass levels and then
showed a progressive decrease by 120 minutes. The variable
response to immediate initiation of bypass (first 2 minutes) is
also seen in changes in PVR. After termination of bypass,
however, PVR uniformly returns to prebypass levels before
increasing, with the increase coincident with deterioration of
fetal gas exchange, as reported previously.4-9 From a hemo-
dynamic standpoint, the first sign of hemodynamic deterio-
ration after bypass typically manifests as an increase in fetal
heart rate followed by a persistent decrease that accompanies
decreasing umbilical blood flows and increasing umbilical
vascular resistance; of note, however, central venous pres-
sure does not change significantly during this time for the
treated animals (6–9 mmHg, data not available for untreated
or control groups), remaining at around the baseline and nor-
mal range for the fetus. Fetal hemodynamics do not change
in the sham/control group.
As reported previously4,8,9,12,14 and in this study, fetal by-
pass leads to significant fetal mixed acidosis, as evidenced by
progressive increases in PCO2 and plasma lactate concentra-716 The Journal of Thoracic and Cardiovascular Sutions during and after bypass (data not shown). Conversely,
the fetal PO2 concentration is stable until the postbypass pe-
riod, when it begins to decrease, typifying the late hypoxia
observed with fetal bypass (data not shown). All 17 fetuses
were successfully weaned off bypass and survived at least
60 minutes of the postbypass period.
Hematocrit and Plasma Volume Changes During
Fetal Bypass
In prior studies we had noted that initiation of bypass was
often associated with increased need for addition of crystal-
loid volume to maintain venous reservoir volume, which
continued into the postbypass period.14 At the same time, of-
ten despite this added volume (and resulting in lower hemat-
ocrit values during bypass), we would see an increase in fetal
hematocrit values in the postbypass period, which is sugges-
tive of possible hemoconcentration. Figure 1, A, shows this
change for hematocrit value in a group of 7 bypass fetuses
compared with control values: for the 2-group repeated-
measures analyses (bypass vs sham), P values were .06 for
time, .16 for group, and .10 for the interaction. Post-hoc
analysis revealed a decrease in hematocrit value with onset
of bypass (P ¼ .038), and subsequent paired t tests showed
hematocrit values remained less than baseline values (P<
.040) until 60 minutes after bypass, whereas sham values
did not change. In this group of animals, volume resuscita-
tion was carried out during bypass to maintain the minimum
reservoir level of 50 mL (as in the treatment group described
next), but no additional volume was given after bypass. The
volume changes during bypass in these 7 animals correlated
with changes in fetal plasma volume (Figure 1, B) from ap-
proximately 79 mL/kg fetal body weight to approximately
72 mL/kg fetal body weight or approximately 8% loss
over a period of 120 minutes. The statistical profile of
plasma volume changes were the same as for hematocrit.
Hematocrit and Plasma Volume Changes After Fetal
Bypass
Hemodynamic stability of individual animals varies dur-
ing the postbypass period; some animals remain stable for
protracted periods, whereas others deteriorate despite beingTABLE 1. Fetal hemodynamics before, during, and after bypass and in-group analysis of variancewith least significant difference post-hoc analysis
Before bypass On bypass 30 Min after bypass 120 Min after bypass In-group ANOVA
FMAP (mm Hg) 37.5  7.0 54.4  11.1 41.4  8.7 32.9  7.1 P< .01
P value .01 .288 .240
HR (beats/min) 137  19 192  32 166  20 162  35 P< .01
P value .01 .010 .036
Umb Q (mL/min) 261  106 390  152 340  123 213  140 P ¼ .016
P value .021 .147 .411
Umb VR (mm Hg $ mL1 $ min1) 0.165  0.093 0.171  0.102 0.142  0.069 0.250  0.194 P ¼ .227
P value .889 .642 .114
Significance at a P value of .05 or less is shown in bold. ANOVA, Analysis of variance; FMAP, fetal mean arterial pressure; HR, heart rate; Umb Q, umbilical blood flow; Umb VR,
umbilical volume resuscitation.rgery c March 2009
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Pexposed to the identical experimental protocol. For this rea-
son, we decided to further examine the use of postbypass
volume resuscitation in a group of 10 fetuses in which vol-
ume resuscitation is carried out to improve or restore fetal
hemodynamics. Figure 2 shows a representative case in
which serial postbypass volume resuscitations in the form
of 5 mL/kg boluses were administered to improve fetal he-
modynamics, as would occur in the clinical setting. Volume
given was in the form of remaining circuit blood. The proto-
col was continued until 120 minutes of observation, when
the experiment was terminated. In Figure 2 each 10 mL of
volume administered (dotted vertical markers no. 7-14) in-
creased fetal mean arterial pressure and umbilical blood
flow. As can be seen, fetal hemodynamics steadily decreased
after cessation of this resuscitation protocol at the end of the
120-minute observation period (after marker no. 14).
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FIGURE 1. Fetal hematocrit levels decreased by 15 minutes of bypass
(n ¼ 7; P<.05, post-hoc analysis) and remained less than prebypass levels
until 30 minutes after bypass (P< .04 vs before bypass, paired t test), fol-
lowed by a sustained increase during the remaining postbypass period
(A). The changes in hematocrit values observed with the bypass animals
did not occur in the sham control animals (n ¼ 9). Prime hematocrit values
averaged 32% and were not an obvious cause of hemodilution. Calculated
fetal plasma volumes during and after bypass (P< .04 vs before bypass)
reveal the presence of a fluid shift in the postbypass period (B). FBW,
Fetal body weight.The Journal of Thoracic andVolume Additions During and After Bypass
To better assess the volume loss associated with fetal by-
pass, we quantified all volume required for maintenance of
the minimum reservoir level during bypass and additional
resuscitation in the postbypass period in the group of treated
animals. Figure 3, A, shows that the largest amounts of fetal
losses occur early and during extracorporeal support. The
volume requirement, however, continues into the postbypass
period (Figure 3, A). These fluid losses correspond to
a dramatic change for the fetus, losing plasma volume or ex-
periencing afluid shift of approximately 0.8mL $ kg1 $min1
(Figure 3, B).
Total TWW
To find out where these fluid losses were occurring in the
fetus, we measured total TWW from numerous sites in
treated animals, as guided by prior literature.17 TTW mea-
surements in myocardium, lung, liver, or kidney samples
demonstrated no differences between the sham and treated
bypass groups (Figure 4, A). Although a few placental sam-
ples suggested mild increases in volume, overall comparison
of serial placental samples from sham animals and animals
undergoing bypass treatment before bypass and 30 and
120 minutes after bypass did not differ within groups or be-
tween the groups (Figure 4, B).
Vasopressin Levels Correlate to Fluid Shift
Vasopressin levels increased dramatically by 30 minutes
of bypass, going from 39 pg/mL before bypass to 51.5 pg/
mL, as we have shown previously.14 Vasopressin levels
were strongly predicted by increased fetal plasma volumes
(R2 ¼ 0.90, Figure 5).
Osmolarity Changes with Fetal Bypass
Vasopressin release can be mediated by the fetal stress re-
sponse, changes in osmolarity, or both. We therefore as-
sessed the potential role of changes in fetal osmolarity in
the observed vasopressin release, particularly in view of
the substantial fluid losses. Plasma osmolarity was calcu-
lated from measured sodium and glucose levels throughout
the protocol. Because of the potential confounding effects
of excessive blood sampling, direct measurement of osmo-
larity (4 mL per sample) was not carried out in these studies,
although we and others have previously shown that mea-
sured and calculated osmolarity are quite congruent.
Calculated fetal osmolarity remained increased after by-
pass in treated fetuses but decreased in nontreated fetuses
(P< .05 at 30 minutes after bypass by using the paired
t test, Figure 6). Osmolarity in sham animals did not change
over time. Although osmolarity in volume-resuscitated ani-
mals went up during the postbypass period versus that seen
in nonresuscitated animals, it was not significant, as deter-
mined by means of repeated-measures analysis, because ofCardiovascular Surgery c Volume 137, Number 3 717
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FIGURE 2. This representative tracing demonstrates the improvement in fetal hemodynamics (blood pressure [FBP] and umbilical blood flow [UmbBF])
with serial fetal transfusions (10 mL each) during the 2-hour postbypass period. Fluid resuscitation was applied each time hemodynamics began to decrease
during the postbypass period (vertical markers 7-14) but not 2 hours after bypass. Note the steady deterioration in fetal hemodynamics by 2 hours after bypass
(marker 15) and beyond when transfusions ceased. UmbVR, Umbilical volume resuscitation.subject loss late in the protocol. The changes in fluid shifts
were not strongly related to changes seen in osmolarity
(R2 ¼ 0.16).
DISCUSSION
This is the first report describing the dramatic fluid shifts
that occur with conduct of fetal bypass. We also demonstrate
that optimizing fetal hemodynamincs after bypass requires
continued volume resuscitation of the fetus, which has sig-
nificant implications for clinical translation of fetal cardiac
surgery, particularly in the context of the current practice
of open fetal surgery. Finally, our results are the first to in-
dicate that bypass-induced fluid shifts are not associated
with significant placental edema, an explanation provided
in the past to account for ongoing placental dysfunction after
bypass.
Large amounts of circuit volume are lost from the reservoir
during fetal extracorporeal support in the absence of obvious
hemorrhage. Furthermore, additional crystalloid volume is
frequently necessary tomaintain safe circuit operation during
the 30 minutes of extracorporeal support, suggesting large
amounts of fluid accumulation or extravasation occurring
somewhere in the fetal–placental unit. Indeed, prior studies
have demonstrated that the pregnant sheep has significant
placental capacitance when driven by pressure and volume
loading15,26 and conversely by excluding the placenta during
bypass,4 suggesting it might accumulate intravascular fluid
(increase capacitance) in the environment of bypass (Table
1). Similarly, increasing extracorporeal perfusion rates718 The Journal of Thoracic and Cardiovascular Sufrom 80 to 110 mL $ kg1 $ min1 in neonatal piglets (fetal
sheep bypass is 200mL $ kg1 $min1) increases fluid extrav-
asation most prominently during bypass,27 as seen in this
study. This latter study also showed that increasing arterial
pressures on bypass, however, does not result in increased
fluid extravasation,24 and conversely, lowering pressure
does not reduce it.25 We therefore suspect that the transient
increase in fetal mean arterial pressure seen with fetal bypass
(within 2 minutes and lasting approximately 5–7 min-
utes)5,6,8 is unlikely to be responsible for the profound fluid
extravasation we observed during bypass in this study.
The profound fluid shifts observed during bypass became
less prominent during the postbypass period, although they
were still persistent. Postbypass volume infusions increased
or restored fetal hemodynamics, although often temporarily,
suggesting that fluid was still actively shifting in the postby-
pass period. Prior studies by Brace and Gold28 examining fe-
tal hemorrhage and intravenous volume loading suggest that
the fetus has 5 to 10 times the interstitial compliance and
capillary filtration coefficient and about one half the vascular
compliance of the adult ewe. Importantly, these prior authors
showed that transplacental fluid movement was not consid-
ered to be a major factor in this dynamic. Thus the need to
continually administer volume to some fetuses throughout
the postbypass period might be a reflection of greater pro-
pensity of the fetus to rapidly move fluids across capillaries
and interstitial space to regulate blood volume (ie, increased
capillary leakage is normal in the fetus). It is also possible
that the fetal endothelial layer is damaged or becomesrgery c March 2009
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Pdysfunctional during the process of fetal bypass.We have re-
cently demonstrated that circulating in vivo nitric oxide
levels decrease in the postbypass period, whereas paradoxi-
cally cyclic guanosine monophosphate levels increase, sug-
gesting that normal vasodilatory mechanisms of the placenta
are disrupted with bypass, an indirect reflection of dysregu-
lation of the fetal endothelial system.9 Further studies exam-
ining endothelial function and integrity in placental and
organ tissues are currently underway in our laboratory.
Our data also suggest that the fluid losses with fetal bypass
are not prominent in the organs we studied. Importantly, and
rather surprisingly, we did not see evidence of placental
edema through our water weight determinations in serial pla-
cental samples collected before and after bypass, a protocol
uniquely possible because of the sheep cotyledonary pla-
centa. We had previously studied placental histology and ar-
chitecture but had never found any profound evidence of
severe edema (data not shown). These histologic studies,
however, are not sensitive enough to detect more subtle de-
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FIGURE 3. For animals in the treated group (n ¼ 10), we tracked volume
additions during bypass and recorded total transfusion amounts during the
postbypass period. Sham animals received no exogenous fluids. Panel A
shows that large amounts of circuit prime volume are lost during 30 minutes
of fetal bypass and that substantial postbypass transfusion volume is also
necessary to maintain fetal hemodynamics. Panel B shows that calculated
fluid shift induced by bypass reveals a dramatic extravasation of plasma vol-
ume during bypass that continued in the postbypass period. Intravascular
fluid loss averaged 0.8 mL $ kg1 $ min1, suggesting the fetal circulation
shifts more than 200 mL of plasma volume over the 150-minute experimen-
tal protocol.The Journal of Thoracic andgrees of fluid accumulation, as assessed by means of stan-
dard TWW analysis. Prior studies in neonatal piglets have
demonstrated that organ edema occurs with normothermic
bypass in the liver, gut, muscle, and skin17 and that hypo-
thermic or high-flow bypass increases edema formation
and edema extends to more organs.17,24 Our studies of
TWW were confined to myocardium, lung, liver, and kid-
neys from treated animals undergoing normothermic bypass
and sham animals. Our model is limited in the application of
before-and-after sampling for certain tissues or organs. Its
possible animals without treatment during bypass could
show water weight changes or that changes are confined to
organs we did not assess (eg, skin, gut, or muscle), but future
studies are planned to address this. The placental samples,
however, do allow for a before-and-after evaluation and as
such do not show evidence of substantial fluid extravasa-
tions and corresponding weight gain in the placenta.
Similarly, we could not measure fetal urine output into the
amniotic cavity (although unlikely in the setting of high
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FIGURE4. Panel A shows the percentage of total tissue water weightmea-
surements in myocardium, lung, liver, or kidney samples and demonstrates
no differences between the sham control animals (n¼ 4, open columns) and
treated bypass groups (n ¼ 6, solid columns) by using the nonparametric
t test. Panel B shows that serial placental samples from sham control animals
(n ¼ 4) and treated bypass animals (n ¼ 4) before bypass and 30 and 120
minutes after bypass did not differ within groups (paired t test) or between
the groups by using the nonparametric Student t test. LV, Left ventricle; RV,
right ventricle.Cardiovascular Surgery c Volume 137, Number 3 719
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Pvasopressin levels, see below) without significant additional
surgical manipulation because a Foley catheter is not feasible
in the fetus. Neither could we measure ‘‘insensible losses’’
with our experimental protocol, which could be significant,
especially in view of the needed fetal chest exposure during
open fetal surgery. Admittedly, our protocol of continued fe-
tal observation in the postbypass period, during which the fe-
tus is exposed, increases the likelihood of insensible losses
that would be perhaps reduced in the clinical setting. Never-
theless, our study highlights that there is potential for signif-
icant fluid losses (0.8 mL $ kg1 $ min1) during fetal
manipulation and exposure to extracorporeal circulation that
should be taken into account in potential conceptualization
of clinical translation. Current practice of open fetal surgery
does not allow for fluid resuscitation of the fetus, at least di-
rectly, after intervention. In a circumstance that placental
transfer of fluids might be limited (as in fetal bypass with
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FIGURE 5. Vasopressin levels increased dramatically from baseline to be-
fore bypass and further throughout bypass. Increasing vasopressin levels
were strongly related to increased fetal plasma volumes (R2 ¼ 0.90, n ¼ 4
animals), suggesting a potential role for vasopressin-mediated osmoregula-
tion.
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FIGURE 6. Plasma osmolarity was calculated from measured sodium and
glucose levels throughout the protocol. Calculated osmolarity remained
higher in treated bypass animals throughout the postbypass period versus
that seen in nontreated bypass animals (P< .05 at 30 minutes after bypass
by using the paired t test), likely reflecting the effect of fluid resuscitation.720 The Journal of Thoracic and Cardiovascular Suassociated placental dysfunction or in the setting of fetal
hydrops, the likely scenario in which this technology would
apply), strong consideration should be given to creating the
means for continued fetal resuscitation and support in the
postsurgical period, as in the form of intracardiac lines, which
is common practice in pediatric cardiac surgery. In our labo-
ratory we have shown that at least in the fetal lamb model,
such an approach can be carried out safely, as in the neonatal
setting.
We and others have previously noted that after bypass the
fetus often needs and might benefit from significant volume
resuscitation.14-16 An alternative explanation for such vol-
ume changes could be changes in fetal fluid reabsorption
at the renal tubules caused by the circulating vasopressin.
Our results suggest that a dramatic increase in the potent va-
soconstrictor vasopressin occurs during bypass that strongly
correlates with the associated decreases in plasma volume.
The changes in vasopressin expression, however, did not
correlate with changes in osmolarity. Further evaluation of
vasopressin receptor expression in the fetus and placenta
along with studies by using vasopressin receptor antagonists
are warranted to further explore the mechanism of fluid shift.
Vasopressin is believed to be the primary mediator of the
fetal stress response and its ‘‘brain-sparing effect.’’29 The
brain-sparing effect is a well-described fetal adaptive mech-
anism that consists of preferential redistribution of fetal cir-
culation to the brain, heart, and adrenals during stress.8,30
This circulatory redistribution is certainly seen with experi-
mental fetal cardiac surgery.8,10 We have previously shown
that significant release of vasopressin (along with other
stress-response hormones) occurs with the conduct of exper-
imental fetal cardiac surgery. These responses appear to re-
flect an overall stimulation of the inflammatory cascade
associated with surgical intervention and extracorporeal cir-
culation. Therefore the increase in vasopressin levels seen in
our study is likely secondary (and not primary) in the ob-
served fluid shifts. Certainly, the significant increases in va-
sopressin would be expected to reduce any fetal urine
output, which would further accentuate the significance of
our fluid losses into fetal tissues.
We also observed that maintenance of baseline osmolarity
during the postbypass period was facilitated by means of
volume resuscitation of the fetus because the sham and non-
resuscitated animals both experienced significant decreases
in osmolarity, primarily because of decreasing sodium
levels. The effects of adult donor prime on fetal osmolarity
must be considered because the calculated osmolarity of
the prime is approximately 290 (sodium and glucose con-
centrations averaging 143 and 75, respectively) compared
with prebypass fetal osmolarity that averages 270 mOsm.
This is intriguing because both bypass groups experienced
the same influence of increased prime osmolarity, yet the an-
imals that were not volume resuscitated in the postbypass
period displayed the same decreasing trend as the controlrgery c March 2009
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Panimals. Examining the osmolarity values on bypass reveals
that no changes in osmolarity occur during bypass, indicat-
ing that prime osmolarity is not influential. This suggests
that postbypass fluid resuscitation of the fetus with isotonic
solutions, but not hypotonic solutions, would be preferable.
In summary, our results suggest that fluid shift in fetal car-
diac surgery with bypass is substantial and begins early dur-
ing bypass but is treatable with vigilant and appropriate fluid
resuscitation during the postbypass period. As such, it is
conceivable that some of the detrimental aspects of fetal by-
pass in prior studies might have been related to the manage-
ment of the fetus before, during, and after bypass (and
management of the fetal stress response) rather than directly
to the effects of exposure to extracorporeal circulation. Min-
iaturization of extracorporeal circuit volume is a necessary
engineering achievement likely to reduce inflammatory
stimuli and should enhance successful fetal bypass, particu-
larly if an oxygenator is used. However, current miniaturized
systems are closed systems and severely limit flexibility
during bypass. Our studies suggest that fluid resuscitation
therapy could potentially improve outcomes and prevent
the postbypass increase in PVR. Indeed, vigilant fluid resus-
citation can ameliorate or stave off the peripheral vasocon-
striction induced by hemoconcentration. Reduction of
these symptoms might ameliorate fetal circulatory centrali-
zation and subsequent placental dysfunction and multiorgan
failure.
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Discussion
Dr James S. Tweddell (Milwaukee, Wis). Thank you, Dr Eght-
esady. You and your colleagues are to be congratulated. That cer-
tainly is a complex animal model that you have chosen to tackle,
and your studies are very interesting.
You have identified and attempted to characterize placental dys-
function and fluid loss in these fetuses, and you have shown that
there are important fluid shifts. You have established that there is in-
travascular fluid loss of 0.8 mL $ kg1 $min1. This does not appear
in any of the major organs, and it does not appear in the placenta ei-
ther. You have concluded, correctly, I think, that placental edema
cannot be implicated as a mechanism of placental dysfunction.
My first question is this: Where do you think the fluid is going?
Dr Eghtesady. We are now starting to look at some other or-
gans, such as the skin, muscle, and gastrointestinal tract, specifi-
cally to see whether it is going there.ardiovascular Surgery c Volume 137, Number 3 721
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PDr Tweddell. Do you have anything you want to share with us
today?
Dr Eghtesady. We have a couple of animals in which there is
some suggestion that the gastrointestinal tract might be the culprit
site, but I think N of 2 is too small to make any conclusions.
Dr Tweddell. You have also measured vasopressin levels
throughout these studies, and others have implicated vasoconstric-
tors as part of the picture of placental dysfunction. In particular, 10
years ago, Frank Hanley demonstrated that products of cyclooxy-
genase might be important, possibly thromboxane or other prosta-
noids. If the production of these agents were blocked with
indomethacin, then the rate of placental dysfunction would be re-
duced. One of the stimuli for vasopressin release is osmolarity,
and you have shown quite nicely that it is probably not the case
here. What is the stimulus for vasopressin release in these fetuses?
Dr Eghtesady. You are absolutely right. We became interested
in this in part because of and building on the work of Dr Hanley and
others, who have shown that fetal stress can be very important in
terms of the evolution of placental dysfunction. Frankly, our dis-
covery of vasopressin was somewhat serendipitous. What I mean
by that is that we had previously looked at different stress response
markers, including b-endorphin, cortisol, and vasopressin, and the
impressive thing that we found was the increases in vasopressin
with fetal surgical bypass. Normally, vasopressin levels are approx-
imately 1 pg/mL in the fetal circulation, and with typical stress,
those levels go up to approximately 10 pg/mL. In our protocol
they increase to greater than 100 pg/mL. It just goes through the
roof. We have also seen that when the level exceeds 90 pg/mL,
those animals invariably do very poorly, whereas the animals that
mount a response that is appropriate but not excessive do well.
The exact mechanism of release of vasopressin in the fetus is still
not known. It is mediated by some effects from the pituitary gland,
but interestingly enough, the placenta and the umbilical cord are not
innervated. Therefore the mechanisms that actually regulate and
perhaps go back and tell the fetus to release this potent hormone,
which happens to be a powerful vasoconstrictor of placental vascu-
lature, are not totally clear to us, and that is one of the things that we
are looking into right now.
Dr Tweddell. Do you think it is a reduction in the atrial filling
pressures with the initiation of bypass, something as simple as that?
Dr Eghtesady. It is possible. But what is interesting, actually, in
the fetus is that we do not see a dramatic decrease in the filling pres-
sures. One of the things that has been impressive to me is that we
often talk about very little pulmonary blood flow in the fetus. Rou-
tinely we actually snare the pulmonary arteries because one of the
things that can happen is that you can have increased pulmonary
blood flow; although not on the percentage level of cardiac output,
it is still not huge. However, one of the things that is often not noted
in the literature that has been found to be very impressive is that
there is substantial aortopulmonary collaterals—or whatever you
want to call them—in terms of bronchial arteries that are equivalent
or greater in their volume of return back to the heart through these
other vessels. Therefore the heart does not completely empty out, as
we normally see in the bypass situation. You actually have to put
a vent separately into the left atrium, even though supposedly there
is a patent foramen ovale.722 The Journal of Thoracic and Cardiovascular SuTherefore I am not sure whether it is necessarily volume. Even
with a vacuum, when we have totally sucked the heart, we still
see the same vasopressin concentration. At this point, I do not
have any thoughts on what is exactly the mechanism.
Dr Tweddell. From amechanistic standpoint, the previous study
suggested that indomethacin might be helpful in this. Have you
considered using peripheral vasodilators, a-antagonists, or some-
thing of that nature? Is that in your future plans?
Dr Eghtesady. We have tried Regitine (phentolamine). We
have not tried phenoxybenzamine. We have tried Nipride (nitro-
prusside), milrinone, and dobutamine, and we are planning to use
some vasopressin antagonists that are now available.
Regitine does not work. For Nipride to work, the concentrations
you have to use are unbelievable. Normally, as you know, in the
clinical setting a half a microgram or maybe a microgram or 2. In
a fetus, to see a response to Nipride in this setting, you have to
go up to 10 to 15 mg $ kg1 $ min1. Milrinone has no effect what-
soever in the fetus.
Therefore of the things that we have tried thus far, we have not
had any success in terms of regulating that. That is why we are in-
terested in the vasopressin antagonist to see whether that works.
Dr Tweddell. Your study is one that could ultimately lead to
a clinical translation. Would you speculate for us on that? Assum-
ing you can get this to work, what would be some of the first lesions
you might tackle?
Dr Eghtesady. One of the ones that we were focusing on in the
laboratory is the intact atrial septum. I think when you see it in the
operating room, it is very clear how thick that is, and when it is truly
an intact septum, it is a challenge.When you look at the literature of
what our cardiology colleagues have tried to dowith stents and those
things, it has not been very effective, certainly in the fetus. Even in
the postnatal setting, often these kids that are coming out, and we
have had this algorithm of being prepared to help these fetuses
out, and they try to do a catheter-based approach to open up the sep-
tum. Invariably in the few cases that I have been involved in, it has
not been successful, and we had to start them on bypass and resect
the atrial septum. Therefore that is themodel onwhichwe have cho-
sen to focus. It is a fairly simple operation. In someways, to me, his-
torically, the very first operations in congenital heart surgery dealt
with the atrial septum. Therefore in a way we thought, ‘‘Let’s start
with that.’’ It is very simple and straightforward.
Dr Tweddell. That is terrific work, and you are to be congratu-
lated for developing this model and getting this underway.
Dr Frank W. Sellke (Boston, Mass). A lot is known about in-
flammatory stimuli in adult bypass, including the effects of neutro-
phils, complement, kinases, and so forth. Do you have any idea
what is going on in the fetus during bypass and then later reperfu-
sion?
Dr Eghtesady. A few studies have been done. We actually
recently got results from a sort of a pseudoproteomics approach
to try to look at this using a panel of antibodies from Kinexis.
Clearly, a number of inflammatory markers are increased. We
are currently digging our way through the data because there
are so many changes. We have noticed a pretty dramatic change
in some of the PKCs and we are trying to figure out what that
means.rgery c March 2009
